Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | N/A | 480,000 | 5,613,000 | 4,566,000 | 6,201,000 |
| Depreciation Amortization | N/A | 2,767,000 | 2,693,000 | 2,103,000 | 2,050,000 |
| Income taxes - deferred | N/A | -1,844,000 | -962,000 | -1,552,000 | -116,000 |
| Accounts receivable | N/A | 139,000 | 157,000 | -406,000 | 313,000 |
| Accounts payable and accrued liabilities | N/A | 290,000 | -347,000 | 226,000 | -118,000 |
| Other Working Capital | N/A | 3,783,000 | -1,148,000 | -819,000 | 489,000 |
| Other Operating Activity | 10,019,000 | 5,213,000 | 2,000,000 | 4,954,000 | 2,565,000 |
| Operating Cash Flow | $10,019,000 | $10,828,000 | $8,006,000 | $9,072,000 | $11,384,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 2,348,000 | -86,000 | 232,000 | -607,000 |
| PPE Investments | N/A | -523,000 | -585,000 | -728,000 | -579,000 |
| Net Acquisitions | N/A | -4,840,000 | -1,152,000 | -1,797,000 | -1,584,000 |
| Purchase Of Investment | N/A | -492,000 | -442,000 | -172,000 | -380,000 |
| Other Investing Activity | -4,793,000 | 58,000 | 0 | -1,000 | 19,000 |
| Investing Cash Flow | $-4,793,000 | $-3,449,000 | $-2,265,000 | $-2,466,000 | $-3,131,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 3,464,000 | 1,980,000 | 0 | N/A |
| Debt Repayment | N/A | -1,970,000 | -2,250,000 | -1,500,000 | -4,750,000 |
| Common Stock Issued | N/A | 422,000 | 232,000 | 309,000 | 169,000 |
| Common Stock Repurchased | N/A | -1,150,000 | -1,000,000 | -1,396,000 | -546,000 |
| Dividend Paid | N/A | -3,918,000 | -3,809,000 | -3,709,000 | -3,605,000 |
| Other Financing Activity | -7,745,000 | -281,000 | -278,000 | -173,000 | -145,000 |
| Financing Cash Flow | $-7,745,000 | $-3,433,000 | $-5,125,000 | $-6,469,000 | $-8,877,000 |
| Exchange Rate Effect | 92,000 | -40,000 | 57,000 | -63,000 | -35,000 |
| Beginning Cash Position | 9,991,000 | 6,085,000 | 5,412,000 | 5,338,000 | 5,997,000 |
| End Cash Position | 7,564,000 | 9,991,000 | 6,085,000 | 5,412,000 | 5,338,000 |
| Net Cash Flow | $-2,428,000 | $3,906,000 | $673,000 | $74,000 | $-659,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 10,019,000 | 10,828,000 | 8,006,000 | 9,072,000 | 11,384,000 |
| Capital Expenditure | N/A | -523,000 | -585,000 | -728,000 | -579,000 |
| Free Cash Flow | 10,019,000 | 10,305,000 | 7,421,000 | 8,344,000 | 10,805,000 |